Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4155/fmc-2020-0180 http://scihub22266oqcxt.onion/10.4155/fmc-2020-0180 32672061!7364852!32672061     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32672061&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Future+Med+Chem 2020 ; 12 (18): 1647-1656 Nephropedia Template TP {{tp|p=32672061|t=2020. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics |pdf=|usr=}}{{32672061}} gab.com Text Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics JO: Future Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32672061 #FOAvip During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of SARS-CoV-2, which involves the host ACE2 receptor and viral spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19. Twit Text FOAVip Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics ????Future Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32672061 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32672061 #FOAvip English Wikipedia <ref>{{Cite pmid|32672061}}</ref> Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics #MMPMID32672061 VanPatten S; He M; Altiti A; F Cheng K; Ghanem MH; Al-Abed Y Future Med Chem 2020[Sep]; 12 (18): 1647-1656 PMID32672061show ga During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of SARS-CoV-2, which involves the host ACE2 receptor and viral spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19. |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Peptides/*therapeutic use[MESH] |Peptidomimetics/*therapeutic use[MESH] |Peptidyl-Dipeptidase A/drug effects[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Spike Glycoprotein, Coronavirus/drug effects[MESH]Evidence supporting the use of peptides and peptidomimetics as potenti(epmc).pdf DeepDyve Pubget Overpricing